
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5778854/publications.pdf Version: 2024-02-01



KENCO FUDUICHI

#	Article	IF	CITATIONS
1	A Case of Repeated Necrotizing Lymphadenitis with <i>MEFV</i> Gene Mutations. Internal Medicine, 2022, , .	0.7	0
2	Soluble receptor for advanced glycation end products protects from ischemia- and reperfusion-induced acute kidney injury. Biology Open, 2022, 11, .	1.2	6
3	Novel PKD2 Missense Mutation p.lle424Ser in an Individual with Multiple Hepatic Cysts: A Case Report. Medicines (Basel, Switzerland), 2022, 9, 25.	1.4	0
4	Cyclin-dependent kinase 4-related tubular epithelial cell proliferation is regulated by Paired box gene 2 in kidney ischemia-reperfusion injury. Kidney International, 2022, 102, 45-57.	5.2	5
5	Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort study. Scientific Reports, 2022, 12, .	3.3	3
6	Steroid-sensitive recurrent mesangial proliferative glomerulonephritis with monoclonal IgG deposits. CEN Case Reports, 2021, 10, 308-313.	0.9	2
7	Rapidly progressive kidney dysfunction and crystal casts associated with adenine phosphoribosyltransferase (APRT) deficiency–lessons for the clinical nephrologist. Journal of Nephrology, 2021, 34, 2147-2149.	2.0	2
8	Carnitine/organic cation transporter 1 precipitates the progression of interstitial fibrosis through oxidative stress in diabetic nephropathy in mice. Scientific Reports, 2021, 11, 9093.	3.3	5
9	Identification of candidate PAX2-regulated genes implicated in human kidney development. Scientific Reports, 2021, 11, 9123.	3.3	7
10	Combined changes in albuminuria and kidney function and subsequent risk for kidney failure in type 2 diabetes. BMJ Open Diabetes Research and Care, 2021, 9, e002311.	2.8	7
11	Two-year longitudinal trajectory patterns of albuminuria and subsequent rates of end-stage kidney disease and all-cause death: a nationwide cohort study of biopsy-proven diabetic kidney disease. BMJ Open Diabetes Research and Care, 2021, 9, e002241.	2.8	2
12	Trajectories of kidney function in diabetes: a clinicopathological update. Nature Reviews Nephrology, 2021, 17, 740-750.	9.6	131
13	A digest from evidence-based Clinical Practice Guideline for Polycystic Kidney Disease 2020. Clinical and Experimental Nephrology, 2021, 25, 1292-1302.	1.6	8
14	Impact of the relationship between hemoglobin levels and renal interstitial fibrosis on long-term outcomes in type 2 diabetes with biopsy-proven diabetic nephropathy. BMC Nephrology, 2021, 22, 319.	1.8	4
15	A digest of the evidence-based Clinical Practice Guideline for Rapidly Progressive Glomerulonephritis 2020. Clinical and Experimental Nephrology, 2021, 25, 1286-1291.	1.6	2
16	A digest from evidence-based clinical practice guideline for IgA nephropathy 2020. Clinical and Experimental Nephrology, 2021, 25, 1269-1276.	1.6	8
17	A digest of the Evidence-Based Clinical Practice Guideline for Nephrotic Syndrome 2020. Clinical and Experimental Nephrology, 2021, 25, 1277-1285.	1.6	21
18	Relationship between anti-erythropoietin receptor autoantibodies and responsiveness to erythropoiesis-stimulating agents in patients on hemodialysis: a multi-center cross-sectional study. Clinical and Experimental Nephrology, 2020, 24, 88-95.	1.6	7

#	Article	IF	CITATIONS
19	Clinicopathological features of fast eGFR decliners among patients with diabetic nephropathy. BMJ Open Diabetes Research and Care, 2020, 8, e001157.	2.8	16
20	Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS). Clinical and Experimental Nephrology, 2020, 24, 893-909.	1.6	6
21	Relationship between autoantibodies to erythropoietin receptor and renal outcome in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Biomarkers, 2020, 25, 194-200.	1.9	1
22	Nonproteinuric diabetic kidney disease. Clinical and Experimental Nephrology, 2020, 24, 573-581.	1.6	47
23	DNA damage in human glomerular endothelial cells induces nodular glomerulosclerosis via an ATR and ANXA2 pathway. Scientific Reports, 2020, 10, 22206.	3.3	6
24	Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study. Nephrology Dialysis Transplantation, 2019, 34, 1182-1188.	0.7	22
25	Association between the recurrence period of acute kidney injury and mortality: a single-centre retrospective observational study in Japan. BMJ Open, 2019, 9, e023259.	1.9	7
26	The involvement of autotaxin in renal interstitial fibrosis through regulation of fibroblast functions and induction of vascular leakage. Scientific Reports, 2019, 9, 7414.	3.3	23
27	Nonproteinuric Versus Proteinuric Phenotypes in Diabetic Kidney Disease: A Propensity Score–Matched Analysis of a Nationwide, Biopsy-Based Cohort Study. Diabetes Care, 2019, 42, 891-902.	8.6	77
28	A case of secondary IgA nephropathy accompanied by psoriasis treated with secukinumab. CEN Case Reports, 2019, 8, 200-204.	0.9	12
29	Amplified Association Between Blood Pressure and Albuminuria in Overweight Patients With Biopsy-Proven Hypertensive Nephrosclerosis. American Journal of Hypertension, 2019, 32, 486-491.	2.0	2
30	Retinopathy progression and the risk of end-stage kidney disease: results from a longitudinal Japanese cohort of 232 patients with type 2 diabetes and biopsy-proven diabetic kidney disease. BMJ Open Diabetes Research and Care, 2019, 7, e000726.	2.8	34
31	Erythropoietin signal protected human umbilical vein endothelial cells from high glucoseâ€induced injury. Nephrology, 2019, 24, 767-774.	1.6	8
32	Association of renal arteriosclerosis and hypertension with renal and cardiovascular outcomes in Japanese typeÂ2 diabetes patients with diabetic nephropathy. Journal of Diabetes Investigation, 2019, 10, 1041-1049.	2.4	8
33	III. Similarity and Difference of Diabetic Nephropathy and Diabetic Kidney Disease. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 681-687.	0.0	Ο
34	Involvement of p38MAPK in Impaired Neutrophil Bactericidal Activity of Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2018, 22, 345-354.	0.9	1
35	Successful treatment of rituximab―and steroidâ€resistant nephrotic syndrome with leukocytapheresis. Journal of Clinical Apheresis, 2018, 33, 409-411.	1.3	2
36	Clinico-pathological features of kidney disease in diabetic cases. Clinical and Experimental Nephrology, 2018, 22, 1046-1051.	1.6	20

#	Article	IF	CITATIONS
37	Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes. Nephrology Dialysis Transplantation, 2018, 33, 138-148.	0.7	62
38	Clinicopathological analysis of biopsy-proven diabetic nephropathy based on the Japanese classification of diabetic nephropathy. Clinical and Experimental Nephrology, 2018, 22, 570-582.	1.6	28
39	Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD. Kidney International Reports, 2018, 3, 133-141.	0.8	11
40	Rationale and study design of a clinical trial to assess the effects of LDL apheresis on proteinuria in diabetic patients with severe proteinuria and dyslipidemia. Clinical and Experimental Nephrology, 2018, 22, 591-596.	1.6	1
41	Decline in estimated glomerular filtration rate is associated with risk of end-stage renal disease in type 2 diabetes with macroalbuminuria: an observational study from JDNCS. Clinical and Experimental Nephrology, 2018, 22, 377-387.	1.6	14
42	Nationwide multicenter kidney biopsy study of Japanese patients with hypertensive nephrosclerosis. Clinical and Experimental Nephrology, 2018, 22, 629-637.	1.6	14
43	Lung cancer in connective tissue disease-associated interstitial lung disease: clinical features and impact on outcomes. Journal of Thoracic Disease, 2018, 10, 799-807.	1.4	19
44	Evaluation of renal oxygen saturation using photoacoustic imaging for the early prediction of chronic renal function in a model of ischemia-induced acute kidney injury. PLoS ONE, 2018, 13, e0206461.	2.5	24
45	Estimated glomerular filtration rate decline and risk of end-stage renal disease in type 2 diabetes. PLoS ONE, 2018, 13, e0201535.	2.5	28
46	Diabetic Nephropathy: A Comparison of the Clinical and Pathological Features between the CKD Risk Classification and the Classification of Diabetic Nephropathy 2014 in Japan. Internal Medicine, 2018, 57, 3345-3350.	0.7	23
47	A new pathological scoring system by the Japanese classification to predict renal outcome in diabetic nephropathy. PLoS ONE, 2018, 13, e0190923.	2.5	24
48	Value of adding the renal pathological score to the kidney failure risk equation in advanced diabetic nephropathy. PLoS ONE, 2018, 13, e0190930.	2.5	18
49	2. Incretin Based Treatments and SGLT2 in Patients with Diabetic Kidney Disease. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 841-847.	0.0	Ο
50	Association of apoptosis inhibitor of macrophage (AIM) expression with urinary protein and kidney dysfunction. Clinical and Experimental Nephrology, 2017, 21, 35-42.	1.6	5
51	Microangiopathic antiphospholipid antibody syndrome due to antiâ€phosphatidylserine/prothrombin complex IgM antibody. Pediatrics International, 2017, 59, 378-380.	0.5	3
52	Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis. Scientific Reports, 2017, 7, 5392.	3.3	63
53	Impairment of the carnitine/organic cation transporter 1–ergothioneine axis is mediated by intestinal transporter dysfunction in chronic kidney disease. Kidney International, 2017, 92, 1356-1369.	5.2	39
54	Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clinical and Experimental Nephrology, 2016, 20, 342-370.	1.6	85

#	Article	IF	CITATIONS
55	Effect of Autoantibodies to Erythropoietin Receptor in Systemic Lupus Erythematosus with Biopsy-proven Lupus Nephritis. Journal of Rheumatology, 2016, 43, 1328-1334.	2.0	14
56	Inhibition of NLRP3 inflammasome as a therapeutic intervention in crystal-induced nephropathy. Kidney International, 2016, 90, 466-468.	5.2	5
57	An autopsy case of vertebrobasilar dolichoectasia under hemodialysis due to autosomal dominant polycystic kidney disease. CEN Case Reports, 2016, 5, 51-55.	0.9	5
58	Risk factors associated with relapse or infectious complications in Japanese patients with microscopic polyangiitis. Clinical and Experimental Nephrology, 2016, 20, 703-711.	1.6	20
59	Messenger RNA expression profile of sleep-related genes in peripheral blood cells in patients with chronic kidney disease. Clinical and Experimental Nephrology, 2016, 20, 218-225.	1.6	12
60	Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD. Clinical and Experimental Nephrology, 2016, 20, 195-203.	1.6	37
61	Relationship between Serum Uric Acid Levels and Chronic Kidney Disease in a Japanese Cohort with Normal or Mildly Reduced Kidney Function. PLoS ONE, 2015, 10, e0137449.	2.5	24
62	A case of a patient with afebrile convulsions diagnosed as having renal coloboma syndrome with <i>PAX2</i> gene mutation. Japanese Journal of Pediatric Nephrology, 2015, 28, 158-163.	0.0	0
63	Impact of kidney function and urinary protein excretion on intima–media thickness in Japanese patients with type 2 diabetes. Clinical and Experimental Nephrology, 2015, 19, 909-917.	1.6	9
64	Calciphylaxis induced by warfarin therapy in a patient with anti-phospholipid antibody syndrome associated with systemic lupus erythematosus. CEN Case Reports, 2015, 4, 169-173.	0.9	2
65	Serum tau protein as a marker of disease activity in enterohemorrhagic Escherichia coli O111-induced hemolytic uremic syndrome. Neurochemistry International, 2015, 85-86, 24-30.	3.8	11
66	Association of PAX2 and Other Gene Mutations with the Clinical Manifestations of Renal Coloboma Syndrome. PLoS ONE, 2015, 10, e0142843.	2.5	40
67	Pro-inflammatory/Th1 gene expression shift in high glucose stimulated mesangial cells and tubular epithelial cells. Biochemical and Biophysical Research Communications, 2014, 443, 969-974.	2.1	13
68	Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency. Clinical and Experimental Nephrology, 2014, 18, 305-312.	1.6	55
69	Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clinical and Experimental Nephrology, 2014, 18, 613-620.	1.6	127
70	Japan Diabetic Nephropathy Cohort Study: study design, methods, and implementation. Clinical and Experimental Nephrology, 2013, 17, 819-826.	1.6	8
71	Nodular lesions and mesangiolysis in diabetic nephropathy. Clinical and Experimental Nephrology, 2013, 17, 3-9.	1.6	27
72	Long-Term Outcomes of Japanese Type 2 Diabetic Patients With Biopsy-Proven Diabetic Nephropathy. Diabetes Care, 2013, 36, 3655-3662.	8.6	122

#	Article	IF	CITATIONS
73	The Impacts of Albuminuria and Low eGFR on the Risk of Cardiovascular Death, All-Cause Mortality, and Renal Events in Diabetic Patients: Meta-Analysis. PLoS ONE, 2013, 8, e71810.	2.5	73
74	Three cases of pneumatosis intestinalis presenting in autoimmune diseases. Modern Rheumatology, 2012, 22, 610-615.	1.8	16
75	Fas Ligand Has a Greater Impact than TNF-α on Apoptosis and Inflammation in Ischemic Acute Kidney Injury. Nephron Extra, 2012, 2, 27-38.	1.1	18
76	Effects of adipose-derived mesenchymal cells on ischemia–reperfusion injury in kidney. Clinical and Experimental Nephrology, 2012, 16, 679-689.	1.6	55
77	Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clinical and Experimental Nephrology, 2012, 16, 903-920.	1.6	91
78	Clinical impact of albuminuria in diabetic nephropathy. Clinical and Experimental Nephrology, 2012, 16, 96-101.	1.6	38
79	Matrix metalloproteinase-2 (MMP-2) and membrane-type 1 MMP (MT1-MMP) affect the remodeling of glomerulosclerosis in diabetic OLETF rats. Nephrology Dialysis Transplantation, 2011, 26, 3124-3131.	0.7	23
80	Fibrocytes in Renal Fibrosis. , 2011, , 229-241.		0
81	Involvement of CD11b+ GR-1low cells in autoimmune disorder in MRL-Fas lpr mouse. Clinical and Experimental Nephrology, 2010, 14, 411-417.	1.6	44
82	A case of neurosarcoidosis with necrotizing granuloma expressing angiotensin-converting enzyme. Modern Rheumatology, 2010, 20, 506-510.	1.8	3
83	Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clinical and Experimental Nephrology, 2009, 13, 9-14.	1.6	82
84	Chemokine Receptor CCR1 Regulates Inflammatory Cell Infiltration after Renal Ischemia-Reperfusion Injury. Journal of Immunology, 2008, 181, 8670-8676.	0.8	79
85	Chemokine Receptor CX3CR1 Regulates Renal Interstitial Fibrosis after Ischemia-Reperfusion Injury. American Journal of Pathology, 2006, 169, 372-387.	3.8	121
86	Gene Therapy via Blockade of Monocyte Chemoattractant Protein-1 for Renal Fibrosis. Journal of the American Society of Nephrology: JASN, 2004, 15, 940-948.	6.1	164
87	Pathologic findings of initial biopsies reflect the outcomes of membranous nephropathy. Kidney International, 2004, 65, 148-153.	5.2	48
88	Blockade of CCR2 Ameliorates Progressive Fibrosis in Kidney. American Journal of Pathology, 2004, 165, 237-246.	3.8	292
89	Effective therapeutic strategies of oral vitamin D3 and intravenous maxacalcitol on secondary hyperparathyroidism in chronic hemodialysis patients: a prospective trial. Nihon Toseki Igakkai Zasshi, 2004, 37, 223-229.	0.1	0
90	Gene Therapy Expressing Amino-Terminal Truncated Monocyte Chemoattractant Protein-1 Prevents Renal Ischemia-Reperfusion Injury. Journal of the American Society of Nephrology: JASN, 2003, 14, 1066-1071.	6.1	93

#	Article	IF	CITATIONS
91	A New Anti-Inflammatory Compound, FR167653, Ameliorates Crescentic Glomerulonephritis in Wistar-Kyoto Rats. Journal of the American Society of Nephrology: JASN, 2000, 11, 1534-1541.	6.1	41
92	Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy. Journal of Leukocyte Biology, 1998, 63, 493-499.	3.3	91
93	Clinicopathologic features of glomerular lesions associated with hepatitis C virus infection in Japan. Clinical and Experimental Nephrology, 1997, 1, 216-224.	1.6	11
94	Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCPâ€1). FASEB Journal, 1996, 10, 1418-1425.	0.5	192
95	Steroid Pulse Therapy in Lupus Cystitis Internal Medicine, 1996, 35, 155-158.	0.7	22
96	A case of chronic hemodialysis with hepatocellular carcinoma and hypercalcemia-clinical significance of PTH-related protein in chronic dialysis patients Nihon Toseki Igakkai Zasshi, 1996, 29, 1081-1085.	0.1	0